The Life Sciences team advised Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”) on entering a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (“Lilly”) to develop a novel oral treatment for obesity and other metabolic diseases. Under the terms of the collaboration, Nimbus is eligible to receive upfront and near-term milestone payments totaling $55 million, with eligibility to receive up to approximately $1.3 billion in total including development, commercial, and sales milestone payments, as well as tiered royalties on global net sales.
Nimbus Therapeutics is a structure-based drug discovery company developing breakthrough small molecule medicines through AI-enhanced computational chemistry. Nimbus pursues well-validated but difficult-to-drug targets with high potential to transform patients’ lives. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus’ pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in Phase 1/2 development for microsatellite instability high (MSI-H) tumors, a salt-inducible kinase 2 (SIK2) inhibitor advancing toward first-in-human studies for inflammatory and autoimmune diseases, and multiple preclinical programs in oncology, immunology, and metabolic diseases. The company is headquartered in Boston, Mass.
The Goodwin deal team was led by Sarah Solomon and Emily Beman and consisted of Bill Collins, Dan Karelitz, Susan Lee, Matt Wetzel, and Justin Pierce.
For more information on the deal, please read the press release.